###begin article-title 0
Erythropoietin Down-Regulates Stem Cell Factor Receptor (Kit) Expression in the Leukemic Proerythroblast: Role of Lyn Kinase
###end article-title 0
###begin p 1
Conceived and designed the experiments: FMG. Performed the experiments: OK DB IG ND. Analyzed the data: OK DB IG ND. Contributed reagents/materials/analysis tools: OK FMG. Wrote the paper: FMG.
###end p 1
###begin p 2
###xml 196 201 196 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Overexpression of the transcription factor Spi-1/PU.1 by transgenesis in mice induces a maturation arrest at the proerythroblastic stage of differentiation. We have previously isolated a panel of spi-1 transgenic erythroleukemic cell lines that proliferated in the presence of either erythropoietin (Epo) or stem cell factor (SCF). Using these cell lines, we observed that EpoR stimulation by Epo down-regulated expression of the SCF receptor Kit and induced expression of the Src kinase Lyn. Furthermore, enforced expression of Lyn in the cell lines increased cell proliferation in response to Epo, but reduced cell growth in response to SCF in accordance with Lyn ability to down-regulate Kit expression. Together, the data suggest that Epo-R/Lyn signaling pathway is essential for extinction of SCF signaling leading the proerythroblast to strict Epo dependency. These results highlight a new role for Lyn as an effector of EpoR in controlling Kit expression. They suggest that Lyn may play a central role in during erythroid differentiation at the switch between proliferation and maturation.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 186 189 186 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Munugalavadla1">[1]</xref>
###xml 592 595 592 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Nocka1">[2]</xref>
###xml 597 600 597 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Geissler1">[3]</xref>
###xml 618 626 618 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in utero</italic>
###xml 1174 1177 1174 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Wu1">[4]</xref>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
###xml 563 567 <span type="species:ncbi:10090">mice</span>
###xml 586 590 <span type="species:ncbi:10090">mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 848 852 <span type="species:ncbi:10090">mice</span>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
Erythropoiesis is critically regulated by a number of growth factors acting through specific receptors, among which erythropoietin (Epo) and stem cell factor (SCF) are essential factors [1]. SCF, the ligand for the Kit receptor, is mainly involved in the survival and proliferation of immature erythroid progenitors, whereas Epo is the predominant regulator preventing apoptosis at the CFU-E/proerythroblast stage of differentiation. The importance of the SCF/Kit pathway during erythropoiesis was highlighted in mice with inactivating mutation in the SCF (Sl/Sl mice) or Kit gene (W/W mice) [2], [3]. Mutant mice die in utero between day 14-16 of gestation with anemia and a profoundly reduced number of erythroid progenitors in fetal liver demonstrating the proliferative function mediated by Kit during early stages of erythropoiesis. Likewise, mice with null mutations in the genes encoding either Epo or EpoR die at midgestation with a severe anemia. Fetal livers from these mice contain BFU-E and CFU-E progenitors, although in reduced number, indicating that the Epo/EpoR pathway is crucial in regulating survival, proliferation and terminal differentiation of CFU-E [4]. Thus, Epo and SCF are growth factors working synergistically to support erythropoiesis, with SCF exerting a predominant role to expand early progenitors, while Epo is acting later on to sustain maturation.
###end p 4
###begin p 5
###xml 285 288 285 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Katayama1">[5]</xref>
###xml 290 293 290 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Uoshima1">[6]</xref>
###xml 420 423 420 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Fraser1">[7]</xref>
###xml 425 428 425 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Wognum1">[8]</xref>
Signaling induced by Epo/EpoR and SCF/Kit is determined by the temporal and spatial expression of their cognate receptors at the surface of responsive cells. Kit is expressed from the earliest committed erythroid progenitor up to the basophilic erythroblastic stage of differentiation [5], [6]. EpoR expression arises at the BFU-E stage, reaches a maximum at the CFU-E and proerythroblast stages and declines thereafter [7], [8].
###end p 5
###begin p 6
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 225 228 225 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-MoreauGachelin1">[9]</xref>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Iwasaki1">[10]</xref>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Scott1">[13]</xref>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 617 620 617 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-MoreauGachelin1">[9]</xref>
###xml 622 626 622 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Rimmele1">[14]</xref>
###xml 682 686 682 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Guillemin1">[15]</xref>
###xml 939 944 939 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 1028 1036 1028 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 209 224 <span type="species:ncbi:10090">transgenic mice</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
In an attempt to dissect the signaling determinants controlling the expression of EpoR and Kit, we used proerythroblastic cell lines isolated during the preleukemic step of erythroleukemia developing in spi-1 transgenic mice [9]. The spi-1 gene encodes the ETS transcription factor Spi-1/PU.1, a main player regulating the commitment of multipotent hematopoietic progenitors and the development of the B lymphoid and monocytic lineages [10]-[13]. Germline overexpression of the spi-1 transgene induces a differentiation arrest in the erythroid lineage at the CFU-E/proerythroblast transition leading to severe anemia [9], [14]. In response to anemia, Epo production is up-regulated [15] causing a massive expansion of proerythroblasts in the hematopoietic tissues of diseased mice. It is likely that SCF expressed by stromal cells in spleen and marrow microenvironments also contributes to the expansion of these proerythroblasts. Indeed, spi-1 transgenic proerythroblasts express both Epo and SCF receptors and can be expanded in vitro in the presence of Epo or SCF.
###end p 6
###begin p 7
###xml 531 534 531 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi</italic>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Using cell lines established from the spleen of various diseased mice, we observed that each of these cell lines exhibited a particular growth rate in response to either Epo alone or SCF alone, and expressed EpoR and Kit in a ratio modulated by the cytokine used to sustain their proliferation. Starting from this observation, we investigated the molecular mechanisms controlling the expression of Kit and EpoR. We show that Epo down-regulated Kit expression and induced expression of the Lyn kinase. When ectopically expressed in spi-transgenic proerythroblasts, Lyn favored cell proliferation in response to Epo, but not to SCF. These biological effects are consistent with the ability of Lyn to induce a down-regulation of Kit expression. Our findings reveal a novel aspect of signaling crosstalk between Kit and EpoR and highlight a central role for Lyn in SCF signaling extinction at the CFU-E/proerythroblast stage.
###end p 7
###begin title 8
Materials and Methods
###end title 8
###begin title 9
Cell lines and proliferation assays
###end title 9
###begin p 10
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 108 111 108 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-MoreauGachelin1">[9]</xref>
###xml 303 304 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 178 184 <span type="species:ncbi:9913">bovine</span>
The spi-1-transgenic proerythroblastic cell lines (633, 663, 812) have been previously described in details [9]. Cells were grown in alpha MEM medium supplemented with 10% fetal bovine serum (FBS) and SCF or Epo or both cytokines in combination at the indicated concentrations. Cells were plated at 2x105 cells/mL and the number of living cells was monitored at 48 hours by Trypan blue exclusion using a Vi-Cell analyzer (Beckman Coulter, Villepinte, France). For cytokine switching experiments, exponentially growing cells were washed 3 times in MEM and then plated at 2x105 cells/mL in culture medium with the cytokines indicated. AG490 (Calbiochem, Strasbourg, France) and JAK inhibitor1 (Calbiochem, Strasbourg, France) were used at a concentration of 10 microM and 20 nM, respectively.
###end p 10
###begin title 11
Flow cytometry and antibodies
###end title 11
###begin p 12
###xml 129 131 123 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2b</sub>
Untreated cells were incubated for 30 min at 4degreesC with Phycoerythrin (PE)-conjugated anti-CD117 (c-Kit) or PE-conjugated IgG2b control monoclonal antibodies (BD Pharmingen, Strasbourg, France). After washing, cells were analyzed on a FACsort(R) with the Cellquest software package (Becton Dickinson, Meylan, France).
###end p 12
###begin title 13
DNA constructs and transfection
###end title 13
###begin p 14
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 163 165 163 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 157 165 157 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MT-Lyn<sup>WT</sup></italic>
###xml 268 273 268 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 265 273 265 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn<sup>Y397F</sup></italic>
###xml 321 323 321 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 315 323 315 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MT-Lyn<sup>WT</sup></italic>
The wild-type (WT) Lyn cDNA was amplified by RT-PCR from mRNAs prepared from 663 cells. The Myc epitope (MT) was added at the cDNA C-terminus by PCR and the MT-LynWT construct was cloned into the pEF-BOS expression vector by standard cloning procedures. The mutant LynY397F cDNA was generated by mutagenesis of the MT-LynWT construct using the quickchange site-directed mutagenesis system (Stratagene, La Jolla, CA) according to the manufacturer's recommendations. Cells were nucleofected with 5 microg of plasmid using an Amaxa nucleofector (Amaxa Biosystems, Koln, Germany). Stable transfectants were selected in growth medium containing 800 microg/mL G418 (Invitrogen, Cergy, France) and Epo (1 U/mL).
###end p 14
###begin title 15
Western blotting and antibodies
###end title 15
###begin p 16
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Barnache1">[16]</xref>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Casteran1">[17]</xref>
###xml 148 154 <span type="species:ncbi:9986">rabbit</span>
Whole cell extracts were fractionated by SDS-PAGE, blotted and visualized as previously described [16]. The following primary antibodies were used: rabbit anti-Kit antibodies provided by P. Dubreuil (Inserm, Marseille, France) [17] or from Cell Signaling (Beverly, MA), anti-EpoR, anti-Lyn and anti-Stat5 antibodies from Santa Cruz Biotechnology (Santa Cruz, California), anti-phosphotyrosine 4G10 clone from Upstate Biotechnology (Lake Placid, NY), anti-phospho-c-Kit (Tyr719) and anti-phospho-Stat5 (Tyr694) from Cell Signaling (Beverly, MA), anti-beta actin antibody from Sigma-Aldrich (St Louis, MO) and anti-myc (epitope 9E10) from Roche Diagnostics (Mississauga, Ontario, Canada).
###end p 16
###begin title 17
Semiquantitative RT-PCR
###end title 17
###begin p 18
###xml 42 45 42 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-MoreauGachelin1">[9]</xref>
###xml 191 194 191 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
###xml 205 208 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 210 213 210 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 210 241 210 241 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene"><italic>Kit</italic>-fw5&#8242;-TCCTCgCCTCCAAgAATTg-3&#8242;</named-content>
###xml 246 249 246 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 246 280 246 280 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene"><italic>Kit</italic>-rev 5&#8242;-ggAAgCCTTCCTTgATCATC-3&#8242;</named-content>
###xml 282 286 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
###xml 282 317 282 317 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene"><italic>EpoR</italic>-fw 5&#8242;- ggCTCCgAAgAAcTTCTgTg-3&#8242;</named-content>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
###xml 322 358 322 358 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene"><italic>EpoR</italic>-rev 5&#8242;- CCAggAgCACTACTTCATTg-3&#8242;</named-content>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 360 393 360 393 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene"><italic>Lyn</italic>-fw 5&#8242;-GATCCAGAGGAACAAGGTGA-3&#8242;</named-content>
###xml 398 401 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 398 432 398 432 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene"><italic>Lyn</italic>-rev 5&#8242;-TGACATCACCATGCATAGGG-3&#8242;</named-content>
RNAs were prepared as previously descibed [9]. RNAs were reverse transcribed using Superscript II reverse transcriptase (Invitrogen). cDNAs were amplified by RT-PCR with specific primers for Kit, EpoR and Lyn: Kit-fw5'-TCCTCgCCTCCAAgAATTg-3' and Kit-rev 5'-ggAAgCCTTCCTTgATCATC-3', EpoR-fw 5'- ggCTCCgAAgAAcTTCTgTg-3' and EpoR-rev 5'- CCAggAgCACTACTTCATTg-3', Lyn-fw 5'-GATCCAGAGGAACAAGGTGA-3' and Lyn-rev 5'-TGACATCACCATGCATAGGG-3'.
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
Kit expression is modulated by cytokines
###end title 20
###begin p 21
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 158 161 158 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-MoreauGachelin1">[9]</xref>
###xml 200 208 200 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 267 271 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Kosmider1">[18]</xref>
###xml 542 551 542 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g001">Figure 1A</xref>
###xml 882 891 882 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g001">Figure 1B</xref>
###xml 1062 1066 1062 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Gouilleux1">[19]</xref>
###xml 1068 1072 1068 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Wakao1">[20]</xref>
###xml 1294 1303 1294 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g001">Figure 1B</xref>
###xml 1720 1729 1720 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g001">Figure 1B</xref>
###xml 2126 2135 2126 2135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g001">Figure 1C</xref>
###xml 142 157 <span type="species:ncbi:10090">transgenic mice</span>
The three proerythroblastic cell lines (633, 663, 812) used in this study were derived from erythroleukemic spleens of three individual spi-1 transgenic mice [9]. The cells were continously amplified in vitro in the presence of either Epo (1 U/mL) or SCF (100 ng/mL) [18]. Each cell line exhibited characteristic proliferation rates that were reproducibly observed over times. In response to either Epo or SCF, 633 cells were highly proliferative, 663 cells showed an intermediary proliferation rate and 812 cells proliferated at a low rate (Figure 1A). To gain insights into the possible causes leading to proliferation rate disparity, we analyzed the expression level of receptors for Epo (EpoR) and SCF (Kit) by immunoblotting. Different levels of EpoR expression were detected in each cell line, but these levels were comparable whether the cells were cultured with Epo or SCF (Figure 1B). Unexpectedly, the highest EpoR levels were seen in 812 cells that proliferated poorly in response to Epo. To check for EpoR activity, we analyzed Stat5 phosphorylation [19], [20]. Phosphorylated Stat5 (P-Stat5) was detected in the 3 cell lines grown with Epo with the highest level seen in 812 cells that exhibited the highest EpoR expression level. P-Stat5 was undetectable in cells grown with SCF (Figure 1B). Next, we analyzed Kit expression levels in the 3 cell lines grown under the 2 cytokines conditions. Clearly, Kit levels were high in cells exhibiting a robust proliferative response to SCF (cell lines 633 and 663). As a read out for Kit activity, detection of the phosphorylated-Y719-Kit form was performed by immunoblotting. P-Y719-Kit was clearly seen in all cells grown with SCF, but not in Epo-cultured cells (Figure 1B). Strikingly, total Kit expression levels were significantly higher in cells grown with SCF compared to cells grown with Epo. Modulation in Kit expression was also detected at the surface of cells grown with Epo or SCF by flow cytometry analysis. The mean Kit-specific fluorescence (MFI) level was increased about 2.5 fold in 663 and 812 cells cultured with SCF compared to cells grown with Epo (Figure 1C). Similar results were obtained for 633 cells (data not shown). Collectively, these data suggested that cytokines could modulate Kit expression levels in leukemic proerythroblastic cells, while no major effect were seen on Epo-R expression.
###end p 21
###begin title 22
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
Proliferation of spi-1 transgenic proerythroblasts and expression of EpoR, Kit and Stat5.
###end title 22
###begin p 23
A: Cells were continuously cultured in the presence of Epo (1 U/mL) or SCF (100 ng/mL). Number of living cells was monitored at 24, 48 and 72 hours using the Trypan blue exclusion staining and a Vi-Cell analyzer (Becton Coulter). Mean number of living cells and standard deviations were determined from 3 independent experiments performed in duplicate. B: Representative Western blot of lysates from cells grown with Epo (1 U/mL) or SCF (100 ng/mL). Antibodies raised against the proteins are indicated on the left of the panel. P-Stat5 and P-Kit antibodies detect Stat5 and Kit phosphorylated forms. The blot was probed with an anti-beta-actin antibody to visualize the protein loading. The membrane was exposed in an Imager, and the resulting signal was quantified using the ImageGauge software package (Fuji, Paris, France). Values were normalized to beta actin expression. The fold change in Kit expression between Epo or SCF-cultured cells is indicated at the bottom of each cell line. C: Representative diagram of flow cytometry analysis showing cell surface expression of Kit in 663 and 812 cells cultured with Epo (dotted line) or SCF (black line). Control IgG profile is shown in grey. The table indicates the mean fluorescence intensity (MFI)+/-SD of positive cells from four independent experiments.
###end p 23
###begin title 24
Kit expression is under Epo control
###end title 24
###begin p 25
###xml 328 337 328 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g002">Figure 2A</xref>
###xml 536 545 536 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g002">Figure 2B</xref>
###xml 1071 1080 1067 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g002">Figure 2C</xref>
###xml 1334 1343 1330 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g002">Figure 2B</xref>
Next, we compared the EpoR and Kit expression levels in the cell lines cultured in a combination of Epo+SCF (SCF was added in Epo-cultured cells for 5 days) to cells cultured with either Epo alone or SCF alone. On Western blotting, Kit expression levels were high with SCF alone, but significantly reduced when Epo was present (Figure 2A). Similarly, cell surface modulation of Kit expression was also detected by flow cytometry analysis with a Kit-specific MFI higher in cells grown with SCF alone than in cells expanded with Epo+SCF (Figure 2B). These data were evocative of a modulation of Kit expression by Epo. To check this hypothesis, we investigated the effects of AG490 and JAK inhibitor 1, both inhibiting Jak2 kinase activity. P-Stat5 was used as a read out for the inhibitory effects of AG490 and JAK inhibitor 1. Both inhibitors had similar effects and only data with AG490 were shown. After a 48 hrs exposure to AG490 (10 microM), P-Stat5 was undetectable on Western blotting in cells cultured with Epo (1 U/mL), although total Stat5 levels were unchanged (Figure 2C). Strikingly, inhibition of EpoR signaling in AG490-treated cells was accompanied by an increase in Kit expression as compared to untreated cells. The Kit increase was also detected at the cell surface of AG490-treated cells by flow cytometry analysis (Figure 2B). Altogether, these data indicated that the modulation of Kit expression was dependent on Jak2 activity and suggested that activation of EpoR could act as a repressor of Kit expression.
###end p 25
###begin title 26
Down-regulation of Kit expression by Epo.
###end title 26
###begin p 27
###xml 2157 2160 2134 2137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 2165 2169 2142 2146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
###xml 2323 2326 2300 2303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 2328 2332 2305 2309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
###xml 2336 2341 2313 2318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
A: Kit and EpoR expression were studied in the 633, 663 and 812 cells grown continuously in the presence of either Epo (1 U/mL) or SCF (100 ng/mL) or a combination of Epo (1 U/mL)+SCF (100 ng/mL). Whole cell lysates were subjected to Western blot analysis with antibodies directed against Kit, EpoR and beta-actin as a loading control. Western blots are from a representative experiment. The membrane was exposed in an Imager, and the resulting signal was quantified using the ImageGauge software package (Fuji, Paris, France). Values were normalized to beta actin expression. The fold change in Kit expression between SCF-cultured cells and either Epo or Epo+SCF-cultured cells is indicated under Kit immunoblotting. B: Representative diagram of flow cytometry analysis showing Kit membrane expression in cells cultured with SCF (100 ng/mL; black line) or Epo+SCF (dotted line). Control IgG profile is shown in grey. The table indicates the mean fluorescence intensity (MFI)+/-SD of four independent experiments. C: AG490 inhibits the down-regulation of Kit by Epo. Cells were cultured for 48 hrs in a medium containing 10% FBS, 1 U/mL Epo and in the presence or absence (-) of AG490 (10 microM). Representative Western blot analysis of whole cell lysates with antibodies directed against Kit, Stat5 and phosphorylated Stat5. beta-actin was used as loading control. The fold change in Kit expression between AG490-treated and untreated cells is indicated under Kit immunoblotting. Representative diagram of flow cytometry analysis showing Kit membrane expression in 663 and 812 cells cultured with Epo and treated (black line) or not (dotted line) with AG490 (10 microM) for 48 hrs. Control IgG profile is shown in grey. The table indicates the mean fluorescence intensity (MFI)+/-SD of positive cells in three independent experiments. D: Cells were cultured for 24, 48 and 72 hrs in the presence of a combination of Epo (1 U/mL)+SCF (100 ng/mL) or Epo (0.1 U/mL)+SCF (100 ng/mL) and viable cells were numbered. Data are mean+/-SD of five experiments, each performed in duplicate. E: The regulation of Kit expression is transcriptional: RT-PCR analysis of Kit and EpoR transcripts in 633, 663 and 812 cells cultured in the presence of either Epo (1 U/mL) or SCF (100 ng/mL). cDNAs were amplified with specific primers for Kit, EpoR or gapdh as control.
###end p 27
###begin p 28
###xml 155 164 155 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g002">Figure 2D</xref>
###xml 290 299 290 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g001">Figure 1A</xref>
###xml 512 521 512 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g002">Figure 2D</xref>
###xml 579 588 579 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g001">Figure 1A</xref>
We next assessed whether the modulation of Kit expression by Epo affected the proliferation of cells cultured in the presence of a combination of Epo+SCF (Figure 2D). When Epo (1 U/mL) was combined with SCF (100 ng/mL) cell growth was similar to that in the presence of Epo (1 U/mL) alone (Figure 1A), indicating that Epo and SCF did not cooperate for cell proliferation. In contrast, a cooperative effect on proliferation was observed when SCF (100 ng/mL) was combined to Epo at a limiting dilution (0.1 U/mL) (Figure 2D) since cell growth was comparable to Epo alone (1 U/mL) (Figure 1A). These data indicated that the low expression of Kit was the reason why Epo at high dose did not cooperate with SCF.
###end p 28
###begin p 29
###xml 188 191 188 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 231 234 231 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">kit</italic>
###xml 367 376 367 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g002">Figure 2E</xref>
###xml 403 407 403 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
###xml 465 468 465 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 571 575 571 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
To learn more about the molecular mechanisms involved in the Epo-dependent regulation of Kit protein expression, we first investigated whether this process was associated to variations in Kit transcription. The expression level of kit transcripts was analyzed by semi-quantitative RT-PCR using RNAs extracted from cells cultured in the presence of either Epo or SCF (Figure 2E). The expression level of EpoR transcripts was similarly investigated. Amplification of Kit transcripts was elevated in SCF-cultured cells but was poorly efficient in Epo-cultured cells whereas EpoR transcript levels were not affected by cytokines. These data strongly suggested that the regulation of Kit expression by Epo was dependent on a transcriptional process.
###end p 29
###begin title 30
Reversible down-regulation of Kit in response to Epo
###end title 30
###begin p 31
###xml 629 638 629 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g003">Figure 3A</xref>
###xml 734 743 734 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g003">Figure 3B</xref>
###xml 986 1000 986 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g003">Figures 3A, 3B</xref>
###xml 1169 1178 1169 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g003">Figure 3C</xref>
The above data were obtained with cells continously cultured with Epo or SCF. Thus, we cannot exclude that they reflected the abilities of Epo and SCF to favor some cell selection rather than a genuine process of response to cytokines. Thus, we investigated whether Kit levels could be reversibly modulated in response to a change in cytokines. 663 and 812 cells cultured in the continuous presence of Epo (1 U/mL) were extensively washed and then switched to SCF (100 ng/mL). 48 hrs later, cell extracts were analyzed by immunobloting with an anti-Kit antibody. Switching from Epo to SCF induced a marked increase in Kit level (Figure 3A). Reciprocally, Kit levels were decreased when cells were switched from SCF to Epo for 48 hrs (Figure 3B). These variations in Kit expression were also detected at the cell surface by flow cytometry analysis. The Kit-specific MFI was increased when cells were switched from Epo to SCF and conversely was decreased after switching from SCF to Epo (Figures 3A, 3B). When cells continuously grown with SCF were switched to various concentrations of Epo for 48 hrs, Kit expression levels were reduced in an Epo-dose dependent manner (Figure 3C). The rapid up or down modulation of Kit levels in response to cytokine changes, the absence of cell death (data not shown) during cytokine changes and the reversibility of the phenomenon indicated that they did not result from a selection process. We thus concluded that activation of Epo-R could mediate a fine regulation on Kit expression.
###end p 31
###begin title 32
Reversible down-regulation of Kit in response to Epo.
###end title 32
###begin p 33
Switch from Epo to SCF (A) and switch from SCF to Epo (B): 663 and 812 cells continuously cultured with Epo (1 U/mL) or SCF (100 ng/mL) were extensively washed with medium without cytokine and then expanded for 48 hrs with SCF (100 ng/mL) or Epo (1 U/mL), respectively. Whole cell lysates were subjected to Western blot analysis with antibodies directed against Kit, EpoR and beta-actin as a loading control. The fold change in Kit expression following the switch in cytokines is indicated under Kit immunoblotting. Representative diagrams of flow cytometry analysis showing Kit expression on the surface of cells expanded with Epo (dotted line) or SCF (black line). Control IgG profile is shown in grey. The tables indicate the mean fluorescence intensity (MFI)+/-SD of positive cells in at least four independent experiments. C: Switch from SCF to various concentrations of Epo. 663 cells cultured with SCF (100 ng/mL) were extensively washed with medium without cytokine and then expanded for 48 hrs with Epo at doses indicated. Whole cell lysates were subjected to Western blot analysis with antibodies directed against Kit, EpoR and beta-actin as a loading control. The fold decrease in Kit expression following the switch from SCF to various doses of Epo is indicated under Kit immunoblotting. Western blots are from a representative experiment repeated 3 times.
###end p 33
###begin title 34
Lyn is a downstream Epo-R effector expressed in response to Epo
###end title 34
###begin p 35
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Tan1">[21]</xref>
###xml 555 564 555 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g004">Figure 4A</xref>
###xml 1281 1290 1281 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g004">Figure 4B</xref>
###xml 1621 1630 1621 1630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g004">Figure 4C</xref>
###xml 1886 1891 1882 1887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
The next issue was to identify the effectors downstream of EpoR that may participate in the regulation of Kit expression. According to the known function of Src kinases in signaling from growth factors receptors [21], we investigated the expression of Src kinases in 633, 663 and 812 cells when cultured either in the presence of Epo or SCF. The expression of Lyn, Lck and Src could be detected in these cells. We found that Lyn expression was different according to the cytokines added in the culture medium. Immunoblotting with the anti-Lyn antibody in Figure 4A showed that Lyn was expressed in cells cultured with Epo but not with SCF. In contrast, no differences in Lck and Src expressions were observed that cells were cultured with either Epo or SCF (data not shown). Of note, Lyn expression profiles differed in each cell lines and correlated with EpoR expression levels. Thus, we investigated whether Epo could regulate Lyn expression. SCF-cultured cells were extensively washed in culture medium with no cytokine and then cultured for 48 hrs in the presence of increasing Epo concentrations. Immunoblotting of cell extracts with the anti-lyn antibody revealed that Lyn expression was induced in a dose dependent manner with levels readily detectable at 0.25 U/mL of Epo (Figure 4B). Likewise, P-Stat5 activation levels increased with Epo concentration. Thus, Epo induced both Lyn expression and Stat5 activation in a dose-dependent manner. To conclusively confirm the role of EpoR activation in the modulation of Lyn expression, the effect of AG490 on Lyn expression level was investigated by Western blotting (Figure 4C). Lyn expression was abolished when AG490 (10 microM) was added in the culture medium containing Epo, which indicated that Lyn expression was dependent on EpoR/Jak2 activation. Together, these data demonstrated that Lyn expression is under Epo control in spi-1 transgenic proerythroblasts.
###end p 35
###begin title 36
Epo controls Lyn expression.
###end title 36
###begin p 37
###xml 1043 1046 1030 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 1201 1204 1188 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 1208 1213 1195 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">gapdh</italic>
A: Lyn and EpoR expression were studied in 633, 663 and 812 cells continuously grown in the presence of either Epo (1 U/mL) or SCF (100 ng/mL). Whole cell lysates were subjected to Western blot analysis with antibodies directed against Lyn, EpoR and beta-actin as a loading control. B: Switch from SCF to Epo induces the expression of Lyn. 663 and 812 cells cultured with SCF (100 ng/mL) were extensively washed with medium without cytokine and then expanded for 48 hrs with Epo at the indicated doses. Whole cell lysates were subjected to Western blot analysis with antibodies directed against Lyn, Stat5, phosphorylated-Stat5 and beta-actin as loading control. C: AG490 inhibits the expression of Lyn. 663 and 812 cells were cultured for 48 hrs in a medium containing 10% serum in the presence or absence of AG490 (10 microM) and in the presence of Epo (1 U/ml). Whole cell lysates were subjected to Western blot analysis with antibodies to Lyn, EpoR and beta-actin. Western blots are from a representative experiment. D: RT-PCR analysis of Lyn transcription in 633, 663 and 812 cells cultured in the presence of either Epo (1 U/mL) or SCF (100 ng/mL). DNAs were amplified with specific primers for Lyn or gapdh as control.
###end p 37
###begin p 38
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 241 244 241 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
###xml 299 308 299 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g004">Figure 4E</xref>
###xml 362 365 362 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lyn</italic>
To determine whether the variations in Lyn protein expression were associated to variations in the expression level of Lyn transcripts, RT-PCR analyses of RNAs prepared from cells continuously cultured with either Epo or SCF were performed. Lyn transcripts were only detected in Epo-cultured cells (Figure 4E) suggesting that Epo might transcriptionally control Lyn expression.
###end p 38
###begin title 39
Lyn down-regulates Kit expression
###end title 39
###begin p 40
###xml 214 216 214 216 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 507 509 507 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 656 658 656 658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 783 792 783 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g005">Figure 5A</xref>
###xml 946 948 946 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 965 967 965 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 986 995 986 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g005">Figure 5A</xref>
###xml 1129 1133 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Tilbrook1">[22]</xref>
###xml 1166 1171 1166 1171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 1304 1313 1304 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g005">Figure 5B</xref>
###xml 1335 1340 1335 1340 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
To explore whether Lyn was a link between EpoR activation and Kit down-regulation, we used an enforced expression strategy. An expression vector encoding Lyn tagged with a Myc epitope (MT) at the C-terminus (MT-LynWT) and the neomycine resistance gene (NeoR) was stably transfected in Epo-cultured 663 cells. Control cells were transfected with an empty vector encoding NeoR. G418-selected clones were selected in the presence of Epo and then amplified in the presence of Epo or SCF. Among those, two MT-LynWT and two control clones were studied in details and gave similar results. Only data with one clone are shown herein. Expression of exogenous MT-LynWT was detected by Western blotting with an anti-MT antibody and Lyn global expression was measured with an anti-Lyn antibody (Figure 5A). Whether transfected cells were cultured with Epo (1 U/mL) or SCF (100 ng/mL), Kit expression levels were markedly decreased in cells overexpressing LynWT (compare 663-LynWT to 663-neo cells, Figure 5A). In contrast, EpoR expression was not affected. Next, we generated a vector encoding a dominant-negative form of Lyn (mutant Y397F) [22] tagged in its C-terminus (MT-LynY397F) to inhibit Lyn function. Stable G418-resistant transfectants were selected and amplified in the presence of Epo. As illustrated in Figure 5B, expression of MT-LynY397F detected by immunoblotting with the MT antibody was associated with an increase in Kit level in the Epo-cultured cells. Thus, Lyn inactivation by a dominant-negative mutant allowed an up-regulation of Kit expression.
###end p 40
###begin title 41
###xml 17 19 17 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 27 32 27 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
Expression of LynWT and LynY397F in 663 cells.
###end title 41
###begin p 42
###xml 60 62 60 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 408 410 405 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 523 528 520 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 595 600 592 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 878 883 872 877 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 983 985 977 979 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1011 1012 1005 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1267 1268 1259 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1352 1357 1344 1349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 1383 1384 1375 1376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1600 1602 1590 1592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1624 1629 1614 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 1782 1783 1772 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
(A) A clone of 663 cells stably transfected with pEF-neo LynWT or pEF-Neo empty vector was expanded in the presence of Epo (1 U/mL) or SCF (100 ng/mL). Whole cell extracts were subjected to Western blot using anti-MT, anti-Lyn, anti-EpoR, anti-Kit antibodies and anti-beta actin as a loading control. The fold increase in Lyn expression and the fold decrease in Kit expression between pEF-Neo and pEF-neo LynWT transfected cells are indicated under Lyn or Kit immunoblotting. (B) 663 cells were transfected with pEF-neo LynY397F or pEF-Neo empty vector. Proliferation of 663 cells expressing LynY397F and cultured in the presence of Epo (1 U/mL). Whole cell extracts were subjected to Western blot using an anti-MT, anti-Lyn, an EpoR, an anti-Kit and an anti-beta actin antibody as a loading control. The fold increases in Lyn and Kit expressions between pEF-Neo and pEF-neo LynY397F transfected cells are indicated under Lyn or Kit immunoblotting. C: Transfected 663-neo and 663-LynWT cells were plated at 2x105 cells/mL in medium containing Epo or SCF at concentrations indicated or with no cytokine. Viable cells were scored after 48 hours. Data are mean+/-SD of five independent experiments performed in triplicate. *indicates statistical significance by student t test: P<.05 compared with the control neo-cells. D: Transfected 663-neo and 663-LynY397F cells were plated at 2x105 cells/mL in the presence of increasing concentrations of Epo and viable cells were scored after 48 hours. Data are mean+/-SD of five independent experiments performed in triplicate. Results are shown for one 663-LynWT clone and one 663-LynY397F clone. Experiments were performed with another clone in each category and similar results were obtained. *indicates statistical significance by student t test: P<.05 compared with the control neo-cells.
###end p 42
###begin p 43
###xml 354 356 354 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 510 519 510 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g005">Figure 5C</xref>
###xml 561 563 561 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 605 610 605 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Y397F</sup>
###xml 807 816 807 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g005">Figure 5D</xref>
###xml 920 922 920 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 991 1000 991 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005721-g005">Figure 5C</xref>
The biological consequences of Lyn overexpression were examined by studying cell proliferation over a 48 hrs period. Transfected cells continuously maintained in Epo before and during the selection process remained strictly Epo dependent since no growth occurred in the absence of Epo. At the three Epo concentrations tested, the number of living 663-LynWT cells was approximately 2-fold increased compared to control 663-neo cells indicating that overexpression of Lyn was associated with a growth advantage (Figure 5C). In contrast to cells overexpressing LynWT and grown with Epo, the growth of 663-LynY397F cells in the presence of Epo was reduced compared with control cells indicating that the dominant negative Lyn mutant was able to counteract the ability of Lyn to favor Epo-induced proliferation (Figure 5D). An opposite effect of Lyn was seen when cells were grown with SCF. Indeed, the growth rate of 663-LynWT cells in the presence of SCF was reduced compared to 663-neo cells (Figure 5C). Thus, the intracellular presence of Lyn was not compatible with the expansion of proerythroblastic cells in the presence of SCF. This result is consistent with the ability of Lyn to down-regulate Kit expression.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
During erythropoiesis, SCF and Epo tightly control the pool size of erythroid progenitor cells that will survive, divide or differentiate. From CFU-E to erythroblasts, the subtle balance between Epo and SCF responses results from a gradual decline of Kit expression associated to an increase in EpoR expression. However, the signaling mechanisms underlying the down-regulation of Kit and the up-regulation of EpoR are poorly understood, mainly because of the poor accessibility, the rarity and the transience of the CFU-E. The spi-1 transgenic proerythroblasts no longer undergo differentiation and are arrested at the CFU-E/proerythroblast transition, but these cells retain their dependency to Epo or SCF for survival and proliferation. This experimental system, in which expansion is uncoupled from maturation, was used to examine the mechanisms controlling the proliferative responses of proerythroblasts to Epo or SCF. We show that Epo down-regulates Kit expression and that Lyn kinase behaves as a mediator of SCF signaling through controlling Kit expression.
###end p 45
###begin p 46
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 111 114 111 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-MoreauGachelin1">[9]</xref>
###xml 432 437 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 75 90 <span type="species:ncbi:10090">transgenic mice</span>
The proerythroblastic cell lines derived from the spleen of diseased spi-1 transgenic mice are morphologically [9] and cytologically (our unpublished data) similar, and resemble CFU-E/proerythroblastic cells. They have intrinsic proliferative capacities and express Kit and EpoR at different levels. This heterogeneity may reflect subtle differences in the level at which the maturation arrest provoked by the overexpression of the spi-1 transgene occurred and/or to genetic or epigenetic variability in the cell lines.
###end p 46
###begin p 47
###xml 422 428 422 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 622 629 622 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in fine</italic>
###xml 954 958 954 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Broudy1">[23]</xref>
###xml 960 964 960 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Jahn1">[24]</xref>
###xml 1426 1430 1426 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Panterne1">[25]</xref>
We took advantage of this heterogeneity to investigate the molecular processes involved in the control of Kit and EpoR expression in response to their cognate ligands. Each cell line (six were studied and three are shown) had a proliferation rate in the presence of SCF that was correlated with the level of Kit expression. However, we observed that Kit levels were modulated by the cytokine used to expand the cells (Epo versus SCF) and that this modulation was rapidly reversible by a change in cytokine. Modifications in Kit levels were detected both in whole cell extracts and at the cell surface indicating that they in fine may lead to a modified response to SCF. The variations in surface expression of Kit analyzed by flow cytometry were significantly lower than that of total amount of cellular Kit analyzed by SDS-PAGE. These differences might be a consequence of the occurrence of Kit receptor internalization following SCF-induced activation [23], [24]. Because of the unavailability of EpoR antibodies for flow cytometric analysis, determination of the cell surface expression of EpoR was not performed. However, no obvious variation in EpoR expression could be detected in whole cell extracts whether cells were stimulated with Epo or SCF. The high Kit level in SCF-cultured cells was reminiscent of a mechanism involving SCF as a modulator of its own receptor expression as described for IL-3, CSF-1 and GM-CSF [25]. In contrast, we observed that Kit expression was down-regulated by Epo and that this down-regulation was inhibited by AG490, an inhibitor of EpoR signaling.
###end p 47
###begin p 48
###xml 305 309 305 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Muta1">[26]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Munugalavadla2">[27]</xref>
###xml 560 564 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Yee1">[28]</xref>
###xml 566 570 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Miyazawa1">[29]</xref>
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Kozlowski1">[30]</xref>
###xml 912 915 912 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 994 998 994 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Vitelli1">[31]</xref>
###xml 1010 1014 1010 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Munugalavadla2">[27]</xref>
###xml 1016 1020 1016 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Jing1">[32]</xref>
###xml 1039 1042 1039 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 1126 1129 1126 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
###xml 1236 1239 1236 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kit</italic>
During hematopoiesis, Kit is expressed in immature and lineage progenitors and is down-regulated upon terminal erythroid differentiation. Accordingly, SCF enhances proliferation and retards differentiation of the erythroblasts and forced expression of Kit in erythroid precursors impairs their maturation [26], [27]. Different mechanisms leading to attenuation of Kit signaling have been reported. A mechanism involves SCF binding to Kit that induces a rapid internalization of the ligand-receptor complex and its degradation through an ubiquitination process [28], [29]. Another process refers to the down-regulation of Kit activation by negative effectors such as the SH2-containing protein tyrosine phosphatase SHP1 [30]. Such mechanisms can be ruled in our system since Kit down-regulation was seen in the absence of SCF, when cells were grown with Epo. Others mechanisms involve a regulatory control at the Kit transcriptional level. In erythropoiesis, transcription factors such as Tal-1 [31] and GATA-1 [27], [32] are repressors of Kit transcriptional expression. Our RT-PCR experiments revealed evident differences in Kit transcripts levels in cells cultured with Epo compared to cells cultured with SCF, a higher expression of Kit transcripts being detected in SCF-cultured cells. Though changes in mRNA stability are an alternate mechanism to explain a variation in mRNA amount, it is attempting to speculate that a transcriptional mechanism is most probably involved in the regulation of Kit expression in proerythroblastic cells. More investigations are required to characterize such a mechanism. Our findings of the down-regulation of Kit expression by Epo in the context of a late erythroid progenitor at the transition CFU-E/proerythroblast highlight that Epo is capable to switch off the expression of Kit in maturing erythroblasts. This process may also limit the cooperation between the two cytokines for proerythroblast proliferation and survival.
###end p 48
###begin p 49
###xml 152 160 152 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Wu2">[33]</xref>
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-vonLindern1">[37]</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Kapur1">[38]</xref>
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Li1">[39]</xref>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EpoR</italic>
###xml 698 702 698 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Sato1">[40]</xref>
###xml 806 811 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 1448 1452 1448 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Wu3">[34]</xref>
###xml 1561 1568 1561 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1584 1588 1584 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Waskow1">[41]</xref>
###xml 543 548 <span type="species:ncbi:9606">human</span>
Several laboratories have described synergistic features between Kit and EpoR co-signaling to maintain the growth and survival of erythroid progenitors in vitro[33]-[37]. One mechanism involves EpoR as a direct downstream effector of Kit signaling through transphosphorylation induced by SCF. More indirectly, Kit signaling contributes to the sustained expression of Stat5 protein which can then be activated by Epo [38]. Target gene products of the EpoR-activated Stat5 axis can also contribute to enhance Kit signaling [39]. Finally, in the human hematopoietic stem cell-like cell line HML/SE, stimulation of Kit by SCF activates transcription of the EpoR gene making the cells responsive to Epo [40]. Similarly, we observed a cooperative effect between Epo and SCF for the survival and proliferation of spi-1 transgenic proerythroblasts. It should be noted that cooperation was seen only at a limiting Epo concentration when Kit expression was up-regulated. In contrast, when Epo was used at a suboptimal concentration (1 U/mL) in combination with SCF, Epo was the only player in controlling cell proliferation. It is reasonable to propose that the down-regulation of Kit expression leads to the loss of SCF responsiveness. In this regard, SCF and Epo cooperation would be restricted to early stages of erythropoiesis when Kit level is high. This agrees with data localizing the physical interaction of Kit and EpoR before or at the CFU-E stage [34] and with results indicating that elevated levels of Epo abolish the requirement for SCF-mediated signals in in vivo erythropoiesis [41].
###end p 49
###begin p 50
###xml 281 285 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Harder1">[42]</xref>
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Karur1">[44]</xref>
###xml 521 525 521 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Tilbrook1">[22]</xref>
###xml 527 531 527 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Tilbrook2">[45]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Chin1">[46]</xref>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
Our findings add to our knowledge of Lyn action in erythropoiesis. Analyses of Lyn-deficient mice revealed that CFU-E exhibited a reduced proliferative capacity associated with attenuated responses to Epo and SCF and that erythroblasts presented defects in survival and maturation [42]-[44]. It was thus proposed that Lyn was involved in the expansion of late erythroid progenitors and the development of mature erythroblasts. Lyn has been described as a downstream effector of Epo in promoting erythroid differentiation [22], [45]. Then, Lyn participates in Stat5 activation and phosphorylation of EpoR [46]. Our findings show that Lyn sustains the Epo-dependent proliferation agreeing with a role of Lyn in the proliferation of late erythroid precursor cells. Furthermore, ectopic Lyn overexpression in SCF-cultured cells resulted in a reduction in Kit expression making cells poorly responsive to SCF. This observation underlines a dual role for Lyn as a positive effector in Epo signaling and a negative effector in Kit signaling and presents Lyn as a major mediator of the balance between Epo and SCF responsiveness during proliferation of proerythroblastic cells.
###end p 50
###begin p 51
###xml 59 63 59 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Gouilleux1">[19]</xref>
###xml 65 69 65 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Penta1">[47]</xref>
###xml 147 151 147 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Witthuhn1">[48]</xref>
###xml 213 217 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Tilbrook1">[22]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Chin1">[46]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Kubota1">[49]</xref>
###xml 261 265 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Okutani1">[50]</xref>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Brizzi1">[51]</xref>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-JacobsHelber1">[35]</xref>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Kapur1">[38]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Pircher1">[52]</xref>
###xml 539 543 539 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Arcasoy1">[53]</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Menon1">[54]</xref>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">spi-1</italic>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005721-Tilbrook1">[22]</xref>
###xml 206 212 <span type="species:ncbi:10090">murine</span>
###xml 235 240 <span type="species:ncbi:9606">human</span>
Stat5 phosphorylation is induced by Epo in erythroid cells [19], [47] and this activation depends on kinases associated with EpoR: the Jak2 kinase [48] and tyrosine kinases of the Src family such as Lyn in murine [22], [46] and Src in human erythroblasts [49], [50]. Although the activation of Stat5 downstream of SCF/Kit has been reported in the myeloid MO7e cells [51], it remains infrequent. Indeed, Stat5 is not activated by SCF in the erythroid cell lines HCD57 [35] and G1E-ER2 [38] as well as in primary erythroid progenitors [52], [53], [54]. Similarly, we found that Stat5 was not activated by SCF in spi-1 transgenic proerythroblasts. In contrast, Stat5 was activated by Epo. Because phosphorylated Stat5 levels in cells cultured under Epo paralleled the expression level of Lyn, a prediction could be that Stat5 was an effector downstream of Lyn in Epo-dependent proliferation of cells. Though Stat5 has been characterized as a direct substrat for Lyn during Epo-induced differentiation of the J2E cell line [22], it is not determined whether Lyn induces similar signaling during cell proliferation in response to Epo. Alternatively, Lyn was an Epo-responsive gene and could be a Stat5 transcriptional target gene. Induction of Lyn protein expression by Epo was associated to induction of RNA expression. Further investigation is required to know whether Stat5 controls the transcription of Lyn through direct binding to its transcriptional promoter.
###end p 51
###begin p 52
In conclusion, our findings on the down-regulation of Kit expression by the EpoR/Lyn pathway in the context of a late erythroid progenitor cell (CFU-E/proerythroblast transition) provide some insights into the mechanisms leading to Kit extinction in maturing erythroblasts. We postulate that the control of Kit expression during erythroid development results from interference between Epo and SCF signaling where activation of the EpoR/Lyn pathway would lead the proerythroblast to the strict Epo dependency through mediating extinction of Kit expression. In this light, it will be interesting to determine if such a down-regulation of the activity of a cytokine active on early multipotent progenitors by a cytokine active later on the maturation of a lineage specific progenitor illustrates a general process in the hematopoietic development.
###end p 52
###begin p 53
###xml 193 198 <span type="species:ncbi:9606">human</span>
The authors thank Z. Maciorowski (Cytometry department at Institut Curie) for helpful assistance with flow cytometry and Janssen-Cilag (Issy-les-Moulineaux, France) for the gift of recombinant human Epo. We are grateful to C. Guillouf, P. Rimmele, M. Saison for many helpful discussions and F. Wendling for comments on the manuscript.
###end p 53
###begin title 54
References
###end title 54
###begin article-title 55
Role of c-Kit and erythropoietin receptor in erythropoiesis.
###end article-title 55
###begin article-title 56
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice.
###end article-title 56
###begin article-title 57
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene.
###end article-title 57
###begin article-title 58
Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor.
###end article-title 58
###begin article-title 59
###xml 46 52 <span type="species:ncbi:10090">murine</span>
Stage-specific expression of c-kit protein by murine hematopoietic progenitors.
###end article-title 59
###begin article-title 60
###xml 73 78 <span type="species:ncbi:9606">human</span>
Changes in c-Kit expression and effects of SCF during differentiation of human erythroid progenitor cells.
###end article-title 60
###begin article-title 61
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL.
###end article-title 61
###begin article-title 62
Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin.
###end article-title 62
###begin article-title 63
###xml 11 26 <span type="species:ncbi:10090">transgenic mice</span>
Spi-1/PU.1 transgenic mice develop multistep erythroleukemias.
###end article-title 63
###begin article-title 64
Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation.
###end article-title 64
###begin article-title 65
PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis.
###end article-title 65
###begin article-title 66
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities.
###end article-title 66
###begin article-title 67
PU.1 functions in a cell-autonomous manner to control the differentiation of multipotential lymphoid-myeloid progenitors.
###end article-title 67
###begin article-title 68
Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation.
###end article-title 68
###begin article-title 69
The hypoxic response: huffing and HIFing.
###end article-title 69
###begin article-title 70
Alterations of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways in the erythropoietin-independent Spi- 1/PU.1 transgenic proerythroblasts.
###end article-title 70
###begin article-title 71
Signal transduction by several KIT juxtamembrane domain mutations.
###end article-title 71
###begin article-title 72
###xml 127 131 <span type="species:ncbi:10090">mice</span>
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.
###end article-title 72
###begin article-title 73
Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity.
###end article-title 73
###begin article-title 74
Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways.
###end article-title 74
###begin article-title 75
Functional and biochemical consequences of abrogating the activation of multiple diverse early signaling pathways in Kit. Role for Src kinase pathway in Kit-induced cooperation with erythropoietin receptor.
###end article-title 75
###begin article-title 76
Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells.
###end article-title 76
###begin article-title 77
Signaling via Src family kinases is required for normal internalization of the receptor c-Kit.
###end article-title 77
###begin article-title 78
Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain.
###end article-title 78
###begin article-title 79
###xml 59 64 <span type="species:ncbi:9606">human</span>
IL-3, GM-CSF and CSF-1 modulate c-fms mRNA more rapidly in human early monocytic progenitors than in mature or transformed monocytic cells.
###end article-title 79
###begin article-title 80
###xml 51 56 <span type="species:ncbi:9606">human</span>
Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation.
###end article-title 80
###begin article-title 81
Repression of c-kit and its downstream substrates by GATA-1 inhibits cell proliferation during erythroid maturation.
###end article-title 81
###begin article-title 82
Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3'-kinase, and protein kinase C.
###end article-title 82
###begin article-title 83
Ligand-dependent polyubiquitination of c-kit gene product: a possible mechanism of receptor down modulation in M07e cells.
###end article-title 83
###begin article-title 84
SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.
###end article-title 84
###begin article-title 85
A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodulates c-kit expression in normal erythroblasts.
###end article-title 85
###begin article-title 86
Exchange of GATA factors mediates transitions in looped chromatin organization at a developmentally regulated gene locus.
###end article-title 86
###begin article-title 87
Interaction of the erythropoietin and stem-cell-factor receptors.
###end article-title 87
###begin article-title 88
Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation.
###end article-title 88
###begin article-title 89
Distinct signaling from stem cell factor and erythropoietin in HCD57 cells.
###end article-title 89
###begin article-title 90
###xml 30 35 <span type="species:ncbi:9606">human</span>
Growth and differentiation of human stem cell factor/erythropoietin- dependent erythroid progenitor cells in vitro.
###end article-title 90
###begin article-title 91
The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro.
###end article-title 91
###begin article-title 92
A novel mechanism of cooperation between c-Kit and erythropoietin receptor. Stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin.
###end article-title 92
###begin article-title 93
Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with kit.
###end article-title 93
###begin article-title 94
###xml 131 136 <span type="species:ncbi:9606">human</span>
Induction of the erythropoietin receptor gene and acquisition of responsiveness to erythropoietin by stem cell factor in HML/SE, a human leukemic cell line.
###end article-title 94
###begin article-title 95
###xml 26 30 <span type="species:ncbi:10090">mice</span>
Rescue of lethal c-KitW/W mice by erythropoietin.
###end article-title 95
###begin article-title 96
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage.
###end article-title 96
###begin article-title 97
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1.
###end article-title 97
###begin article-title 98
Lyn kinase promotes erythroblast expansion and late-stage development.
###end article-title 98
###begin article-title 99
Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn.
###end article-title 99
###begin article-title 100
Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway.
###end article-title 100
###begin article-title 101
Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells.
###end article-title 101
###begin article-title 102
JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.
###end article-title 102
###begin article-title 103
Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase.
###end article-title 103
###begin article-title 104
Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway.
###end article-title 104
###begin article-title 105
STAT protein recruitment and activation in c-Kit deletion mutants.
###end article-title 105
###begin article-title 106
Integrative signaling by minimal erythropoietin receptor forms and c-Kit.
###end article-title 106
###begin article-title 107
Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor.
###end article-title 107
###begin article-title 108
Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis.
###end article-title 108
###begin p 109
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 109
###begin p 110
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The work was supported by the Institut National de la Sante et de la Recherche Medicale (Inserm) and Institut Curie, and by grants from Association pour la Recherche sur le Cancer, Ligue contre le Cancer (Equipe labellisee 2006 to F.M.G.), Institut National du Cancer (INCa) and Association Christelle Bouillot. OK was supported by fellowships from Inserm (poste d'accueil), Association pour la Recherche sur le Cancer and Societe Francaise d'Hematologie. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 110

